Category: From KIF1A.ORG

KIF1A.ORG Community, Please help us welcome two interns from the M.A. Program in Biotechnology at Columbia University: Jerry Shen and Michelle Tao! We’re excited to have Jerry and Michelle share their skills and experience with KIF1A.ORG this summer to help advance our mission!

KIF1A.ORG Community, We’re eager to announce the expansion of our efforts to find treatments for KIF1A-Associated Neurological Disorder (KAND) by partnering with the Gennerich Lab at Albert Einstein College of Medicine in New York. Arne Gennerich, Ph.D., is an active member of the KIF1A Research Network and an expert in molecular mechanisms of microtubule-based motor…

KIF1A.ORG Community, KIF1A.ORG is excited to expand our pipeline of therapeutic development projects for KIF1A Associated Neurological Disorder (KAND) through our partnership with Rarebase. Rarebase is a public benefit corporation pioneering a new approach to biotech by partnering with patient communities like ours. They share our sense of urgency and optimism in today’s science to…

Another year has come and gone, and despite the changes and challenges that this year brought for many, the KIF1A.ORG community continued to experience exponential growth thanks to people like you. Real growth. Tangible growth. Growth that will allow THIS generation of individuals living with KIF1A Associated Neurological Disorder (KAND) to realize dreams, gain independence…

KIF1A.ORG introduces a new program to bring support and comfort to KIF1A superheroes undergoing a medical procedure or recovering from an injury. Read on to learn more about this new resource made possible by a partnership with Ryan’s Case for Smiles and Phillies Charities, Inc.

KIF1A.ORG Community, What if KIF1A treatment already existed? It could be on the shelves of your local pharmacy, or a drug created for a related disease like Parkinson’s or epilepsy. Are there FDA-approved treatments for other conditions that could bring relief to KAND patients living with progressive spasticity, uncontrolled seizures or painful neuropathy? We won’t…

KIF1A.ORG Community, Today we’re highlighting the exciting work we’re doing with Albany Molecular Research Inc. (AMRI) to support KIF1A.ORG’s therapeutic development efforts. This project was made possible by a Rising Tides grant awarded by The Child Neurology Foundation to support organizations during the COVID-19 pandemic.

KIF1A.ORG Community, We are thrilled to introduce you to two new staff members: Charlotte Klinepeter, Administrative Manager, and Aileen Lam, Science Communication Associate! Charlotte and Aileen bring valuable strengths and experiences to the organization and expand our capacity to accelerate our mission.

KIF1A.ORG Community, We’re excited to introduce one of our newest partners, the Bařinka Lab at Institute of Biotechnology of the Czech Academy of Sciences in the Czech Republic! Our partnership will enable the Bařinka Lab to collaborate with HNF Pharma Inc. and The Jackson Laboratory to study a potential drug therapy for KIF1A Associated Neurological…

KIF1A.ORG Community,  KIF1A.ORG is excited to share a series of announcements about recently funded projects powered to rapidly discover and develop treatments for people affected by KAND. First up: The McKenney Lab at University of California, Davis. Led by Richard McKenney, PhD, the McKenney Lab has long collaborated with KIF1A.ORG, and leads the field in…

Hello KIF1A.ORG community, Perhaps against all odds, 2020 has been a year of growth for the KIF1A community.